Ascendis Pharma (ASND) Reports Q2 EPS by EUR (1.46)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
August 10, 2022 4:01 PM EDTÂ Â U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022
  SKYTROFA revenue continued to double quarter-to-quarter, reaching 4.4 million in the second quarter
  With anticipated growth in U.S. revenues and approximately 1 billion of cash, cash equivalents, and marketable securities on hand, Ascendis is positioned to fulfill Vision 3x3 and become cash flow positive
  Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:... More
